{"id":"373c4951-c142-59bb-9606-2b9811c702ce","stable_key":"3d41d18a-e13a-59a0-a081-55bfcdd43e55:ceylon-nicotine-clinical","predicate":"has_no_significant_effect_in_trial","statement":"The clinical trial found no significant nicotine AUC change with the characterized C. verum regimen; the geometric mean exposure ratio was 0.98.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"5530492d-05a4-58ea-a2a9-27f119c2a41e","mechanism_event_label":"The large interaction predicted from enzyme models was not seen for nicotine in this human study.","subject":{"id":"26f73b5c-ec9e-519d-884d-513998e64b9d","slug":"ceylon-characterized-pk-product","display_name":"Well-characterized C. verum product in the 2026 interaction trial","entity_type_key":"chemical_species"},"object":{"id":"e5ae1b55-a3d2-59bf-b475-235155097e50","slug":"human-nicotine-auc","display_name":"Measured human nicotine plasma exposure AUC","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"5530492d-05a4-58ea-a2a9-27f119c2a41e","stable_key":"3d41d18a-e13a-59a0-a081-55bfcdd43e55:ceylon-nicotine-clinical-event","event_type":"observed_intervention","label":"The large interaction predicted from enzyme models was not seen for nicotine in this human study.","description":"The clinical trial found no significant nicotine AUC change with the characterized C. verum regimen; the geometric mean exposure ratio was 0.98.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"22c6c620-aea4-55ec-9c2a-3cbf914b8997","slug":"nicotine","display_name":"Nicotine","entity_type_key":"small_molecule"},"role":"measured_drug","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"44b7b150-3615-5d52-9db8-beb212fc31eb","slug":"cyp2a6","display_name":"Human cytochrome P450 2A6 / CYP2A6","entity_type_key":"protein"},"role":"mechanistic_background","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"26f73b5c-ec9e-519d-884d-513998e64b9d","slug":"ceylon-characterized-pk-product","display_name":"Well-characterized C. verum product in the 2026 interaction trial","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"e5ae1b55-a3d2-59bf-b475-235155097e50","slug":"human-nicotine-auc","display_name":"Measured human nicotine plasma exposure AUC","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ceylon-research/41622703.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0d12141499aba319f8c7513f708889a4dc40fae628e26600f780be2323fe0db3\", \"start_char\": 0, \"end_char\": 1643, \"text_sha256\": \"0d12141499aba319f8c7513f708889a4dc40fae628e26600f780be2323fe0db3\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Within-person clinical pharmacokinetic comparison","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Characterized C. verum 2 g three times daily for five days, with day-six drug coadministration and two further cinnamon doses; nicotine gum 2 mg or letrozole 2.5 mg","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Product- and regimen-specific short-term result, not proof of no interaction with all drugs, oils or extracts. CYP2A6 model predictions did not translate into large AUC changes here.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"ceylon","display_name":"Ceylon cinnamon / Cinnamomum verum bark preparations","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The large interaction predicted from enzyme models was not seen for nicotine in this human study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ceylon-p41622703] Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio. (2026). https://pubmed.ncbi.nlm.nih.gov/41622703/ DOI: 10.1002/cpt.70218","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"16 healthy non-nicotine-using adults; plasma drug profiles","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"63abc037-16e5-558c-9170-c3175e6b0b55","evidence_kind":"source_excerpt","locator":"Lines 1195-1206","start_line":1195,"end_line":1206,"excerpt":"### ceylon-nicotine-clinical\nThe clinical trial found no significant nicotine AUC change with the characterized C. verum regimen; the geometric mean exposure ratio was 0.98.\nCondition category: normal\nnutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The large interaction predicted from enzyme models was not seen for nicotine in this human study.\norganism: Human\ntissue_or_cell_type: 16 healthy non-nicotine-using adults; plasma drug profiles\nexperimental_model: Within-person clinical pharmacokinetic comparison\nlimitations: Product- and regimen-specific short-term result, not proof of no interaction with all drugs, oils or extracts. CYP2A6 model predictions did not translate into large AUC changes here.\nexposure: Characterized C. verum 2 g three times daily for five days, with day-six drug coadministration and two further cinnamon doses; nicotine gum 2 mg or letrozole 2.5 mg\nevidence_span: {\"source_cache\": \"artifacts/ceylon-research/41622703.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0d12141499aba319f8c7513f708889a4dc40fae628e26600f780be2323fe0db3\", \"start_char\": 0, \"end_char\": 1643, \"text_sha256\": \"0d12141499aba319f8c7513f708889a4dc40fae628e26600f780be2323fe0db3\"}\n[ceylon-p41622703] Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio. (2026). https://pubmed.ncbi.nlm.nih.gov/41622703/ DOI: 10.1002/cpt.70218","model_system":"Within-person clinical pharmacokinetic comparison","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ceylon-p41622703] Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio. (2026). https://pubmed.ncbi.nlm.nih.gov/41622703/ DOI: 10.1002/cpt.70218","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"3aed3c5b-8016-5e37-ad6f-9019d34d19eb","stable_key":"import-3d41d18a-e13a-59a0-a081-55bfcdd43e55","title":"Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"639b1d8dcff42f2cf1f00a7dc38202289b70213e37c357c375b1f5905d6cf832","revision_id":"9675eb03-ee34-5160-b928-46b6ca9d1ecc","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}